Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, SCIO-469, p38 MAP kinase, myeloma, bone marrow
Brief summary
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.
Detailed description
The main objective of this study is to assess the efficacy of SCIO-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates. Patients took SCIO-469 two capsules (60 mg) by mouth three times a day with water, preferably with a meal, for 72 days except on Days 1 and 30 of monotherapy and Days 1 and 11 of combination therapy. On these days, the second dose of SCIO-469 was administered after collection of the 12-hour PK sample, and the third dose was not administered.
Interventions
DRUGSCIO-469
two 30-mg capsules three times daily
In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
Sponsors
Scios, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Life expectancy more than three months * diagnosed with multiple myeloma (MM) * relapsed following a response to any conventional MM therapy, and refractory to their most recent MM therapy * Karnofsky performance status = 60 * no electrocardiographic evidence of acute ischemia or new conduction system abnormalities * no history of myocardial infarction within last 6 months * serum concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3X upper limit of normal (ULN) * total serum bilirubin = 2X ULN * Calculated or measured creatinine clearance \>30 mL/min * platelet count = 30 x 10(9)/L * hemoglobin concentration = 8 g/dL * white blood cell count = 2.0 x 10(9)/L
Exclusion criteria
* Patients with non-secretory myeloma, plasma cell leukemia, or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) * major surgery within four weeks of enrollment * severe elevated serum calcium * heart failure * receipt of chemotherapy within 21 days before enrollment, receiving immunotherapy, radiation therapy, or other investigational agents * receipt of corticosteroids equivalent to more than 10 mg/day of prednisone within two weeks before enrollment * known allergies to agents used in bortezomib (e.g., boron or mannitol) * poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions. | Day 73 |
Secondary
| Measure | Time frame |
|---|---|
| Time to first response, time to best response, and percentage of patients with disease progression were assessed. | Days 1, 15, 30, 52, and 73 |
| Size and number of lytic bone lesions were summarized. | screening and Day 73 |
| Quality of life and pain was assessed. | Days 1, 15,30,52,73 |
| Performance status was evaluated. | Screening, Days 1, 30, 73 |
| Bone disease was monitored by assessing various markers. | Days 1, 15, 30, 52, 73 |
Outcome results
None listed